Zobrazeno 1 - 10
of 19 633
pro vyhledávání: '"Non-small cell lung cancer (NSCLC)"'
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1297-1320 (2024)
Lung cancer is the leading cause of cancer mortality globally, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Despite advancements in first-line treatments such as immunotherapy and targeted therapies, resistance to these treatm
Externí odkaz:
https://doaj.org/article/b2f01ff1c3c241158e28a564b26abd28
Autor:
An Wang, Tao Li, Yun-ye Mao, Ming Gao, Sheng Shu, Chang-hong Xia, Yi Dong, Min Liu, Jin-liang Wang, Jun-xun Ma, Yi Hu
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Objective The present study endeavors to furnish an exhaustive review of the research advancements on solid tumors harboring RET rearrangement within the Chinese context, particularly emphasizing the examination of real-world therapeutic str
Externí odkaz:
https://doaj.org/article/14da8b0790fc4a759a33afbba168afbc
Autor:
Daniel Breadner, David M. Hwang, Don Husereau, Parneet Cheema, Sarah Doucette, Peter M. Ellis, Shaqil Kassam, Natasha Leighl, Donna E. Maziak, Shamini Selvarajah, Brandon S. Sheffield, Rosalyn A. Juergens
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6017-6031 (2024)
Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely access to comprehensive molecular profiling is critical for selecting biomarker-matched targeted
Externí odkaz:
https://doaj.org/article/f7cb34653c054cd781905d065bb3e78f
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Purpose Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with immune-related adverse events (irAEs). This study analyzes the relationship between irAEs and treatment effectiveness in advanced non-sma
Externí odkaz:
https://doaj.org/article/24f89ff893744ad6999c19926809fba4
Autor:
Ming Li, Yuanyuan Li, Jun Zheng, Zhen Ma, Jianye Zhang, Hao Wu, Yangyang Zhu, Pan Li, Fang Nie
Publikováno v:
Journal of Nanobiotechnology, Vol 22, Iss 1, Pp 1-26 (2024)
Abstract The immunosuppressive tumor microenvironment (TME) significantly inhibits the effective anti-tumor immune response, greatly affecting the efficacy of immunotherapy. Most tumor-associated macrophages (TAMs) belong to the M2 phenotype, which c
Externí odkaz:
https://doaj.org/article/94b4a401689348a28447768f5a8172f3
Autor:
Xixi Zheng, Lili Zhou, Hui Shi, Juan An, Weiran Xu, Xiaosheng Ding, Yichun Hua, Weiwei Shi, Xiaoyan Li
Publikováno v:
Thoracic Cancer, Vol 15, Iss 28, Pp 2029-2037 (2024)
Abstract Background Patients with programmed cell death‐ligand 1 (PD‐L1) ≥50% metastatic non‐small cell lung cancer (NSCLC) treated with first‐line immunotherapy showed heterogeneous tumor responses. In this study, we investigated the clini
Externí odkaz:
https://doaj.org/article/eaa72eb92bbc46599c34cc893044f50d
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract The main bottleneck in training a robust tumor segmentation algorithm for non-small cell lung cancer (NSCLC) on H&E is generating sufficient ground truth annotations. Various approaches for generating tumor labels to train a tumor segmentati
Externí odkaz:
https://doaj.org/article/d3c7dacee6e841c6b4657d2155e93c6c
Autor:
Qingsong Li, Na Liang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long
Externí odkaz:
https://doaj.org/article/11afa3d0e40b46c1b5b170451759b2c5
Autor:
Anqi Wang, Jianjie Zhu, Yue Li, Min Jiao, Saiqun Zhang, Zong-li Ding, Jian-an Huang, Zeyi Liu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract The EphA family belongs to a large group of membrane receptor tyrosine kinases. Emerging evidence indicates that the EphA family participates in tumour occurrence and progression. Nonetheless, the expression patterns and prognostic values of
Externí odkaz:
https://doaj.org/article/257bd1193dc4489f813e92838b8b6e01
Autor:
Hongchao Zhang, Guopei Zhang, Mingyang Xiao, Su Cui, Cuihong Jin, Jinghua Yang, Shengwen Wu, Xiaobo Lu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-24 (2024)
Abstract Background Activator protein-1 (AP-1) represents a transcription factor family that has garnered growing attention for its extensive involvement in tumor biology. However, the roles of the AP-1 family in the evolution of lung cancer remain p
Externí odkaz:
https://doaj.org/article/b229326a244c41b498cf60d8a9882ac9